Table 4.
Grade 3 to 4 treatment-related adverse events
| Adverse events | EC-wPa (n = 259) | EP-wPa (n = 257) |
|---|---|---|
| No. (%) | No. (%) | |
| Hematologic | ||
| Neutropenia | 195 (75.3) | 203 (79.0) |
| Leukopenia | 169 (65.3) | 159 (61.9) |
| Anemia | 8 (3.1) | 5 (1.9) |
| Thrombocytopenia | 5 (1.9) | 4 (1.6) |
| Nonhematologic | ||
| Neuropathy and paresthesiab | 12 (4.6) | 25 (9.7) |
| Arthralgia and myalgia | 26 (10.0) | 21 (8.2) |
| Nausea | 22 (8.5) | 13 (5.1) |
| Fatigue | 16 (6.2) | 22 (8.6) |
| Vomitingc | 19 (7.3) | 8 (3.1) |
| Diarrhea | 5 (1.9) | 5 (1.9) |
| Allergic | 3 (1.2) | 4 (1.6) |
| Edema | 8 (3.1) | 16 (6.2) |
| Stomatitis | 2 (0.8) | 3 (1.2) |
| Constipation | 8 (3.1) | 2 (0.8) |
| Laboratory-assessed items | ||
| Alanine aminotransferase increased | 5 (1.9) | 5 (1.9) |
| Aspartate aminotransferase increased | 6 (2.3) | 6 (2.3) |
| Hyperglycemia | 3 (1.2) | 5 (1.9) |
a
EC-wP = epirubicin/cyclophosphamide followed by weekly paclitaxel; EP-wP = epirubicin/paclitaxel followed by weekly paclitaxel.
b
2-sided P = .02 by χ2 test.
c
2-sided P = .03 by χ2 test.